Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
MLN2238: Mapping Proteasome Stress Signaling
2026-09-25
Explore how MLN2238, a potent proteasome β5 subunit inhibitor, can reveal the signaling response to proteotoxic stress. This article connects proteasome perturbation with ROS–JNK–CREB biology while distinguishing established findings from practical assay hypotheses.
-
Spectrophotometric Assays for Alfuzosin–Tadalafil
2026-09-25
Alqahtani and colleagues developed the first reported spectrophotometric methods for quantifying alfuzosin hydrochloride and tadalafil together in a binary mixture. Their absorbance-subtraction and ratio-difference approaches address overlapping spectra and were validated for tablet analysis, offering simpler alternatives to more instrument-intensive assays without establishing clinical or pharmacological effects.
-
BKT140 (BL-8040) in CXCR4 Oncology Workflows
2026-09-24
Build functional CXCR4 studies around BKT140 (BL-8040): connect receptor expression with chemotaxis, survival, and cell-mobilization readouts. Practical starting conditions and troubleshooting guidance help distinguish target engagement from assay artifacts while keeping imaging evidence in its proper translational context.
-
DMXAA and the Endothelial Logic of Tumor Control
2026-09-24
DMXAA (Vadimezan) offers a way to interrogate tumor-vessel injury, angiogenic signaling, and cell-death responses. Here, we connect its reported pharmacology to new evidence on endothelial STING-JAK1 biology—while keeping the evidence boundaries clear for translational study design.
-
MLN2238: From Proteasome Blockade to Stress Signaling
2026-09-23
Explore MLN2238 as a proteasome β5 subunit inhibitor and a tool for studying how proteotoxic stress reshapes cellular signaling. This article connects its target profile with CRTC–CREB findings and practical assay choices, while distinguishing established evidence from cross-model hypotheses.
-
MLN2238: From β5 Selectivity to Stress Signals
2026-09-23
MLN2238 is a proteasome β5 subunit inhibitor that enables researchers to connect catalytic-site inhibition with ROS, JNK, CREB, and proteostasis outcomes. This article presents a layered assay strategy for distinguishing direct proteasome effects from adaptive stress signaling in oncology and protein-aggregation models.
-
Disulfiram Workflows for Proteasome and Cancer Research
2026-09-22
Disulfiram enables paired studies of copper-sensitive proteasome inhibition, apoptotic cancer cell death, and inflammasome-linked pyroptosis. This workflow emphasizes matched controls, orthogonal readouts, and practical handling conditions for more interpretable cancer research.
-
IBDV VP3 Disrupts IRF7 Antiviral Signaling
2026-09-22
The 2025 Frontiers in Cellular and Infection Microbiology study identifies IBDV VP3 as a viral factor that suppresses IRF7-dependent type I interferon signaling and promotes viral replication through proteasome-associated IRF7 degradation. Its paired infection, genetic perturbation, inhibitor, and protein-interaction experiments provide a useful framework for studying how viral proteins redirect host protein-stability pathways.
-
SARS-CoV-2 ORF3a Q57H Dampens Apoptosis
2026-09-21
The reference study shows that the SARS-CoV-2 ORF3a-Q57H variant reduces pro-apoptotic activity through altered protein localization and weaker activation of the extrinsic apoptotic pathway, rather than through markedly lower total protein expression. Its design separates abundance from function and provides a useful framework for interpreting apoptosis assays and caspase activity measurement in virus–host cell studies.
-
ONX-0914 (PR-957) for LMP7 Assays
2026-09-21
ONX-0914 (PR-957) provides a selective way to interrogate LMP7-driven cytokine signaling in autoimmune, inflammatory, and airway infection assays. This guide translates immunoproteasome biology into practical workflows, with controls that distinguish LMP7-specific effects from solvent toxicity, broad proteasome inhibition, or altered viral burden.
-
AP20187 for Precision Conditional Signaling
2026-09-20
AP20187 is a chemical inducer of dimerization that converts engineered fusion proteins into experimentally controllable signaling switches. This guide connects its conditional activation workflow with macrophage–nociceptor research, while separating established product applications from forward-looking assay opportunities.
-
Bortezomib, Stress Granules, and Translational Strategy
2026-09-19
Bortezomib (PS-341) is more than a reversible 20S proteasome inhibitor: it is a strategic probe for studying how proteostasis, ER stress, stress granules, and apoptosis intersect. This article translates recent HRD1-SEL1L findings into a rigorous framework for oncology and cell-biology research while distinguishing established evidence from testable hypotheses.
-
MG-262: Proteasome Control for Translational Research
2026-09-18
MG-262, also known as Z-Leu-Leu-Leu-B(OH)2, gives translational researchers reversible, cell-permeable control over proteasome chymotryptic activity. This thought-leadership analysis connects proteostasis, BIRC2/BIRC3 inflammatory signaling, apoptosis research, cell cycle arrest studies, fibroblast biology, and osteoclast differentiation inhibition while distinguishing established evidence from testable translational hypotheses.
-
Anti-RPS6 Antibody Workflows for PDAC Research
2026-09-18
Build a practical RPS6 readout across Western blot, immunofluorescence, and immunoprecipitation to connect membrane signaling with ribosome biogenesis in pancreatic cancer models. This guide pairs the Anti-RPS6 (7B10) Mouse Monoclonal Antibody with experimentally actionable controls, optimization steps, and interpretation limits.
-
InstaBlue Protein Stain Solution: Gel Workflow
2026-09-17
InstaBlue Protein Stain Solution provides rapid Coomassie-based visualization of protein bands in polyacrylamide gels without fixation, washing, or destaining. It is suited to routine protein electrophoresis analysis and mass spectrometry workflows, but it should not replace a validated protein quantification assay or protocols designed for membranes and other non-polyacrylamide matrices.